XML 14 R48.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock-based Compensation (Details) (USD $)
12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Securities remaining and available for future issuances (in shares) 17,460,673    
Percentage of price lesser than fair market value per share (in hundredths) 90.00%    
Stock-based compensation $ 3,904,000 $ 3,316,000 $ 3,055,000
Stock Option Activity [Abstract]      
Stock option vesting period 4 years    
Stock option contractual term 10 years    
Stock option vesting provisions 12/48 of a granted award will vest after one year of service, while an additional 1/48 of the award will vest at the end of each month thereafter for 36 months, or· 1/48 of the award will vest at the end of each month over a four-year period.    
Options [Roll Forward]      
Balance as of January 1, 2011 (in shares) 7,457,184    
Granted (in shares) 864,750    
Exercised (in shares) (346,432)    
Expired (in shares) (379,957)    
Cancelled/forfeited (in shares) (850,559)    
Balance as of December 31, 2011 (in shares) 6,744,986 7,457,184  
Vested and expected to vest at December 31, 2011 (in shares) 6,721,818    
Exercisable at December 31, 2011 (in shares) 5,307,773    
Weighted Average Exercise Price [Roll Forward]      
Balance as of January 1, 2011 (in dollars per share) $ 5.13    
Granted (in dollars per share) $ 3.17    
Exercised (in dollars per share) $ 3.05    
Expired (in dollars per share) $ 4.17    
Cancelled/forfeited (in dollars per share) $ 5.34    
Balance as of December 31, 2011 (in dollars per share) $ 5.02 $ 5.13  
Vested and expected to vest at December 31, 2011 (in dollars per share) $ 5.02    
Exercisable at December 31, 2011 (in dollars per share) $ 5.16    
Weighted Average Remaining Contractual Term (Years) [Roll Forward]      
Balance as of December 31, 2011 5 years 5 months 12 days    
Vested and expected to vest at December 31, 2011 5 years 5 months 9 days    
Exercisable at December 31, 2011 4 years 7 months 28 days    
Aggregate Intrinsic Value [Roll Forward]      
Balance 217,028    
Vested and expected to vest at end of the year 215,799    
Exercisable 134,764    
Weighted Average Remaining Contractual Terms (years) [Abstract]      
Total intrinsic value of stock options exercised 311,000 541,000 1,529,000
Black-Scholes-Merton option valuation model based on weighted-average assumptions [Abstract]      
Expected term 5 years 2 months 12 days 5 years 6 months 5 years
Risk-free interest rate (in hundredths) 0.83% 1.95% 2.22%
Volatility (in hundredths) 75.63% 72.36% 72.81%
Dividends (in hundredths) 0.00% 0.00% 0.00%
Resulting weighted average grant date fair value (in dollars per share) $ 1.96 $ 3.24 $ 4.02
Total compensation cost recognized for the stock options and restricted stock awards [Abstract]      
Total compensation cost for share-based payment arrangements recognized in the statement of operations (net of tax of $0) 3,904,000 3,316,000 3,055,000
Total compensation cost for share-based payment arrangements recognized in the statement of operations, tax 0 0 0
Total unamortized compensation cost related to outstanding unvested stock options and restricted stock awards 4,593,000    
Total unamortized compensation cost related to outstanding vested stock options and restricted stock awards 3,918,000    
Weighted average period for recognition of cost 1 year 6 months 22 days    
Cash received from stock option and warrant exercises 1,413,000 2,849,000 7,128,000
Restricted Stock Awards [Member]
     
Restricted Stock Awards, Performance-Based Restricted Stock Awards [Roll Forward]      
Outstanding, Beginning Balance (in shares) 79,741    
Granted (in shares) 280,408    
Exercised/Released (in shares) (50,408)    
Cancelled/forfeited (in shares) (15,000)    
Outstanding, Ending Balance (in shares) 294,741    
Vested and expected to vest at December 31, 2011 (in shares) 294,741    
Exercisable at December 31, 2011 (in shares) 109,241    
Weighted Average Grant Date Fair Value [Roll Forward]      
Balance as of January 1, 2011 (in dollars per share) $ 5.59    
Granted (in dollars per share) $ 3.06    
Exercised/Released (in dollars per share) $ 4.08    
Cancelled/forfeited $ 3.44    
Balance as of December 31, 2011 (in dollars per share) $ 3.55    
Weighted Average Exercise Price [Abstract]      
Balance as of December 31, 2011 (in dollars per share) $ 3.55    
Vested and expected to vest at December 31, 2011 (in dollars per share) $ 3.55    
Exercisable at December 31, 2011 (in dollars per share) $ 3.34    
Weighted Average Remaining Contractual Terms (years) [Abstract]      
Balance as of December 31, 2011 8 years 10 months 24 days    
Vested and expected to vest 8 years 10 months 24 days    
Exercisable at December 31, 2011 8 years 7 months 6 days    
Performance-Based Restricted Stock Awards [Member]
     
Restricted Stock Awards, Performance-Based Restricted Stock Awards [Roll Forward]      
Outstanding, Beginning Balance (in shares) 246,225    
Granted (in shares) 276,375    
Vested (in shares) 0    
Cancelled/forfeited (in shares) (261,300)    
Outstanding, Ending Balance (in shares) 261,300    
Vested (in shares) 0    
Weighted Average Grant Date Fair Value [Roll Forward]      
Balance as of January 1, 2011 (in dollars per share) $ 5.82    
Granted (in dollars per share) $ 3.44    
Cancelled/forfeited $ 5.68    
Balance as of December 31, 2011 (in dollars per share) $ 3.44    
Black-Scholes-Merton option valuation model based on weighted-average assumptions [Abstract]      
Recognized compensation expense related to awards 107,000    
FDA clearance or approval (in hundredths) 40.00%    
Achieving targeted revenue increase (in hundredths) 15.00%    
Entering into a major collaboration for development and/or commercialization of the Company's products (in hundredths) 40.00%    
1997 Plan [Member]
     
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Maximum issuance of common stock (in shares) 7,000,000    
Share-based compensation, expiration date Oct. 22, 2007    
2004 Plan [Member]
     
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Maximum issuance of common stock (in shares) 3,000,000    
Maximum limit for increase in outstanding stock (in hundredths) 2.00%    
Securities remaining and available for future issuances (in shares) 1,419,831    
Employee Stock Purchase Plan [Member]
     
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Maximum issuance of common stock (in shares) 500,000    
Maximum percentage of common stock that may be purchased through payroll deductions (in hundredths) 15.00%    
Common stock issued to employees (in shares) 53,672    
Proceeds from issuance of common stock 100,000    
Stock-based compensation 53,000    
Total compensation cost recognized for the stock options and restricted stock awards [Abstract]      
Total compensation cost for share-based payment arrangements recognized in the statement of operations (net of tax of $0) $ 53,000